Recent Investment Analysts’ Ratings Updates for Soleno Therapeutics (SLNO)

Several analysts have recently updated their ratings and price targets for Soleno Therapeutics (NASDAQ: SLNO):

• 3/14/2026 – Soleno Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/4/2026 – Soleno Therapeutics had its price target lowered by HC Wainwright from $120.00 to $100.00. They now have a “buy” rating on the stock.
• 2/28/2026 – Soleno Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/27/2026 – Soleno Therapeutics had its price target lowered by Wells Fargo & Company from $114.00 to $110.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – Soleno Therapeutics had its price target lowered by TD Cowen from $120.00 to $85.00. They now have a “buy” rating on the stock.
• 2/3/2026 – Soleno Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 1/22/2026 – Soleno Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Soleno Therapeutics had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $114.00 price target on the stock, up from $106.00.
• 1/20/2026 – Soleno Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock, up from $110.00.

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.